Show simple item record

dc.contributor.authorTivey, Ann
dc.contributor.authorHuddar, Prerana
dc.contributor.authorShotton, Rohan
dc.contributor.authorCheese, Imogen
dc.contributor.authorDaniels, Susanna
dc.contributor.authorLorigan, Paul; orcid: 0000-0002-8875-2164
dc.contributor.authorJ Lee, Rebecca; orcid: 0000-0003-2540-2009; email: Rebecca.lee-3@manchester.ac.uk
dc.date.accessioned2021-07-02T14:20:09Z
dc.date.available2021-07-02T14:20:09Z
dc.date.issued2021-07-02
dc.date.submitted2020-11-15
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625117/fon-2020-1165.pdf?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625117/additional-files.zip?sequence=3
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625117/fon-2020-1165.xml?sequence=4
dc.identifier.citationFuture Oncology, volume 0, issue 0
dc.identifier.urihttp://hdl.handle.net/10034/625117
dc.descriptionFrom Future Science Group via Jisc Publications Router
dc.descriptionHistory: received 2020-11-15, pub-print 2021-04, accepted 2021-04-22, online 2021-07-02, pub-electronic 2021-07-02
dc.descriptionPublication status: Published
dc.description.abstractAdvances in research have transformed the management of melanoma in the past decade. In parallel, patient advocacy has gained traction, and funders are increasingly prioritizing patient and public involvement. Here we discuss the ways in which patients and the public can be engaged in different stages of the research process, from developing, prioritizing and refining the research question to preclinical studies and clinical trials, then finally to ongoing research in the clinic. We discuss the challenges and opportunities that exist at each stage in order to ensure that a representative population of patients and the public contribute to melanoma research both now and in the future.
dc.languageen
dc.publisherFuture Medicine Ltd
dc.rightsLicence for this article starting on 2022-07-02: https://www.future-science-group.com/archiving
dc.rightsEmbargo: starts 2021-07-02, ends 2022-07-02, duration 12 months from publication.
dc.sourcepissn: 1479-6694
dc.sourceeissn: 1744-8301
dc.subjectReview
dc.subjectadvocacy
dc.subjectclinical trial
dc.subjectmelanoma
dc.subjectpatient engagement
dc.subjectPPI
dc.subjectresearch
dc.subjectrisk
dc.titlePatient engagement in melanoma research: from bench to bedside
dc.typearticle
dc.date.updated2021-07-02T14:20:09Z
dc.date.accepted2021-04-22


Files in this item

Thumbnail
Name:
fon-2020-1165.pdf
Size:
1.415Mb
Format:
PDF
Thumbnail
Name:
additional-files.zip
Size:
637.1Kb
Format:
Unknown
Thumbnail
Name:
fon-2020-1165.xml
Size:
95.52Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record